Camurati-Engelmann disease:: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment

被引:156
作者
Janssens, K
Vanhoenacker, F
Bonduelle, M
Verbruggen, L
Van Maldergem, L
Ralston, S
Guañabens, N
Migone, N
Wientroub, S
Divizia, MT
Bergmann, C
Bennett, C
Simsek, S
Melançon, S
Cundy, T
Van Hul, W
机构
[1] Univ Antwerp, Dept Med Genet, B-2610 Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Med Genet, Antwerp, Belgium
[3] Univ Hosp Brussels, Dept Med Genet, Brussels, Belgium
[4] Univ Hosp Brussels, Dept Rheumatol, Brussels, Belgium
[5] Inst Pathol & Genet, Ctr Human Genet, Loverval, Belgium
[6] Univ Edinburgh, Rheumat Dis Unit, Edinburgh, Midlothian, Scotland
[7] Hosp Clin Barcelona, Dept Rheumatol, E-08036 Barcelona, Spain
[8] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy
关键词
D O I
10.1136/jmg.2005.033522
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Camurati- Engelmann disease ( CED) is a rare autosomal dominant type of bone dysplasia. This review is based on the unpublished and detailed clinical, radiological, and molecular findings in 14 CED families, comprising 41 patients, combined with data from 10 other previously reported CED families. For all 100 cases, molecular evidence for CED was available, as a mutation was detected in TGFB1, the gene encoding transforming growth factor ( TGF) beta 1. Pain in the extremities was the most common clinical symptom, present in 68% of the patients. A waddling gait ( 48%), easy fatigability ( 44%), and muscle weakness ( 39%) were other important features. Radiological symptoms were not fully penetrant, with 94% of the patients showing the typical long bone involvement. A large percentage of the patients also showed involvement of the skull ( 54%) and pelvis ( 63%). The review provides an overview of possible treatments, diagnostic guidelines, and considerations for prenatal testing. The detailed description of such a large set of CED patients will be of value in establishing the correct diagnosis, genetic counselling, and treatment.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 70 条
  • [1] Transcriptional and post-transcriptional mechanisms of glucocorticoid antiproliferative effects
    Almawi, WY
    Abou Jaoude, MM
    Li, XC
    [J]. HEMATOLOGICAL ONCOLOGY, 2002, 20 (01) : 17 - 32
  • [2] Deflazacort treatment in progressive diaphyseal dysplasia (Camurati-Engelmann disease)
    Bas, F
    Darendeliler, F
    Petorak, I
    Sadikoglu, B
    Bilir, A
    Bundak, R
    Saka, N
    Günöz, H
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1999, 35 (04) : 401 - 405
  • [3] LATENT FORMS OF TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) DERIVED FROM BONE CULTURES - IDENTIFICATION OF A NATURALLY-OCCURRING 100-KDA COMPLEX WITH SIMILARITY TO RECOMBINANT LATENT TGF-BETA
    BONEWALD, LF
    WAKEFIELD, L
    OREFFO, ROC
    ESCOBEDO, A
    TWARDZIK, DR
    MUNDY, GR
    [J]. MOLECULAR ENDOCRINOLOGY, 1991, 5 (06) : 741 - 751
  • [4] SUCCESSFUL TREATMENT WITH CORTICOSTEROID IN A PATIENT WITH PROGRESSIVE DIAPHYSEAL DYSPLASIA
    BOURANTAS, K
    TSIARA, S
    DROSOS, AA
    [J]. CLINICAL RHEUMATOLOGY, 1995, 14 (04) : 485 - 486
  • [5] Phenotypic variability at the TGF-β1 locus in Camurati-Engelmann disease
    Campos-Xavier, AB
    Saraiva, JM
    Savarirayan, R
    Verloes, A
    Feingold, J
    Faivre, L
    Munnich, A
    Le Merrer, M
    Cormier-Daire, V
    [J]. HUMAN GENETICS, 2001, 109 (06) : 653 - 658
  • [6] Camurati M., 1922, CHIR ORG MOVIMENTO, V6, P662
  • [7] GLUCOCORTICOID REGULATION OF TRANSFORMING GROWTH FACTOR-BETA-1 ACTIVITY AND BINDING IN OSTEOBLAST-ENRICHED CULTURES FROM FETAL-RAT BONE
    CENTRELLA, M
    MCCARTHY, TL
    CANALIS, E
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (09) : 4490 - 4496
  • [8] Reduction in transforming growth factor β receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid
    Chang, DJ
    Ji, C
    Kim, KK
    Casinghino, S
    McCarthy, TL
    Centrella, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) : 4892 - 4896
  • [9] Chérie-Ligniére G, 1999, CLIN EXP RHEUMATOL, V17, P264
  • [10] Transforming growth factor-β inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function
    Choy, L
    Derynck, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) : 9609 - 9619